Flunisolide for the treatment of asthma

References

• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2012. Available from: www.ginasthma.org/uploads/users/files/GINA_Report_2012.pdf Last accessed 21 January 2014
   Google Scholar
• National Heart Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the Diagnosis and Management of Asthma Full Report. 2007. Available from: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf Last accessed 21 January 2014
   Google Scholar
• British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma, A national clinical guideline 2012. Available from: www.sign.ac.uk/pdf/sign101.pdf Last accessed 21 January 2014
   Google Scholar
• Lougheed DM; for the CTSACA. Canadian Thoracic Society 2012 Guideline update. diagnosis and management of asthma in preschoolers, children, and adults: executive summary. Can Respir J 2012:19(6):e81-8
   Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: ACCP/ACAAI. Chest 2005;127(1):335-71
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105(6):930-8
   PubMed Web of Science ®Google Scholar
• Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006;100(6):1297-306
   PubMedGoogle Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159(9):941-55
   PubMed Web of Science ®Google Scholar
• Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165(10):1377-83
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Mauger D, Bacharier LB, et al. for the CARE Network of the National Heart, Lung, and Blood Institute. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011;365:1990-2001
   PubMed Web of Science ®Google Scholar
• Papi A, Nicolini G, Baraldi E, et al. on behalf of the BEclomethasone and Salbutamol Treatment (BEST) for Children Study Group. Regular vs prn nebulized treatment in wheeze preschool children. Allergy 2009;64:1463-71
   PubMed Web of Science ®Google Scholar
• Lavorini F, Corrigan CJ, Barnes PJ, et al. for the Aerosol Drug Management Improvement Team. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med 2011;105(7):1099-103
   PubMed Web of Science ®Google Scholar
• Corren J, Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther 2003;25(3):776-98
   PubMed Web of Science ®Google Scholar
• US FDA. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm368237.htm Last accessed 26 January 2014
   Google Scholar
• Valeas. Available from: www.valeas.it/medic/pro/Forbest.aspx Last accessed 24 January 2014
   Google Scholar
• Tevaitalia. Available from: www.tevaitalia.it/it/foglietto-illustrativo/nisolid-monodose.htm Last accessed 24 January 2014
   Google Scholar
• Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998;11384:957-63
   Google Scholar
• Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001;14(2):197-208
   PubMedGoogle Scholar
• van der Wiel E, ten Hacken NH, Postma DS, et al. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013;131(3):646-57
   PubMed Web of Science ®Google Scholar
• Scichilone N, Spatafora M, Battaglia S, et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy 2013;6:11-21
   PubMedGoogle Scholar
• Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042-50
   PubMed Web of Science ®Google Scholar
• Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996;85(9):960-4
   PubMed Web of Science ®Google Scholar
• Nolting A, Sista S, Abramowitz W. Flunisolide HFA vs. flunisolide CFC: pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos 2001;22(9):373-82
   PubMed Web of Science ®Google Scholar
• Nolting A, Abramowitz W. Multiple-dose proportionality study of flunisolide hydrofluoroalkane. Allergy Asthma Proc 2002;23(5):311-18
   PubMedGoogle Scholar
• Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001;87(5):405-11
   PubMed Web of Science ®Google Scholar
• Bensch GW, Greos LS, Gawchik S, et al. Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2011;107(4):323-9
   PubMedGoogle Scholar
• Gillman SA, Anolik R, Schenkel E, Newman K. One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatr (Phila) 2002;41(5):333-40
   PubMedGoogle Scholar
• Kantar A, Mroueh S, Fiocchi A. A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. Allergy Asthma Proc 2007;28(6):671-87
   PubMedGoogle Scholar
• Melani AS. Nebulized corticosteroids in asthma and COPD. An Italian appraisal. Respir Care 2012;57(7):1161-74
   PubMedGoogle Scholar
• Camargo CA Jr, Ramachandran S, Ryskina KL, et al. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm 2007;64(10):1054-61
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Leibman C, Patel P, Camargo CA Jr. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Curr Med Res Opin 2007;23(6):1319-28
   PubMed Web of Science ®Google Scholar
• Marcus P, Oppenheimer EA, Patel PA, et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcome. Ann Allergy Asthma Immunol 2006;96(5):736-43
   PubMedGoogle Scholar
• Hoegger P, Rohdewald P. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother 1998;9:501-22
   Google Scholar
• O’Callaghan C, White J, Jackson J, et al. The output of flunisolide from different nebulisers. J Pharm Pharmacol 2002;54(4):565-9
   PubMedGoogle Scholar
• O’Callaghan C, White JA, Jackson JM, et al. Nebulisation of corticosteroids suspensions and solutions with a 2-agonist. J Pharm Pharmacol 2008;60(5):601-5
   PubMedGoogle Scholar
• O’Callaghan C, White JA, Kantar A. Nebulization of corticosteroids to asthmatic children: large variation in dose inhaled. Respirology 2014;19(2):276-9
   PubMedGoogle Scholar
• Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003;112:58-63
   PubMed Web of Science ®Google Scholar
• Bergeron C, Hauber HP, Gotfried M, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005;116(5):983-9
   PubMed Web of Science ®Google Scholar
• Price D, Martin RJ, Barnes N, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010 126(3):511-18
   Google Scholar
• Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011;41(11):1521-32
   PubMedGoogle Scholar
• Colice G, Martin RJ, Israel E, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013;132(1):45-54
   PubMed Web of Science ®Google Scholar
• Rottier BL, Rubin BK. Asthma medication delivery: mists and myths. Paediatr Respir Rev 2013;14(2):112-18
   PubMedGoogle Scholar
• Robinson CA, Tsourounis C. Inhaled corticosteroid metered-dose inhalers: how do variations in technique for solutions versus suspensions affect drug distribution? Ann Pharmacother 2013;47(3):416-20
   PubMedGoogle Scholar
• ZuWallack RL, Rosen JP, Cohen L, et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immuol 1997;99(3):278-85
   PubMedGoogle Scholar
• Kantar A, Carloni M, Kulkarni N, et al. Retention of flunisolide in rat lungs after single inhalation. Eur J Inflammation 2012;10(1):127-31
   Google Scholar
• Moore CD, Roberts JK, Orton CR, et al. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos 2013;41(2):379-89
   PubMed Web of Science ®Google Scholar